The objective of this paper is to elucidate the role of specific cytokines in lupus (SLE) arthritis.
Methods
Fifty SLE and 40 RA patients had an ultrasound (US) scan of their hand as per standardized protocols. US scores were expressed per joint and as a total ‘US activity’ score, (sum of power Doppler (PD) and grey-scale synovial hypertrophy scores in all joints) and a total erosion score. SLE disease activity was assessed (BILAG and SELENA-SLEDAI). Plasma levels of IL-6, TNF-alpha and BLyS were measured using sandwich ELISA kits (Quantikine kits, R & D).
Results
On the basis of the US results SLE patients were divided into three groups: erosive arthritis (n = 20), non-erosive arthritis (n = 18) and those with a normal US scan (n = 12). Across the SLE groups plasma IL-6 levels correlated with CRP (p < 0.001), hand deformity scores (p = 0.005), BILAG musculoskeletal score (p = 0.009), wrist PD score (p = 0.01), the presence of tenosynovitis (p = 0.008) and total US activity score (p < 0.001) (which remained constant when corrected for total BILAG score). Neither TNF-alpha nor BLyS levels correlated with US or clinical measures of lupus arthritis; however, TNF-alpha correlated with total BILAG score (p < 0.001).
Conclusion
This is the first study to examine levels of specific cytokines in a cohort of SLE patients stratified in terms of joint disease by US, where the most significant finding is that IL-6 levels correlated both with clinical and US measures of arthritis disease activity.
AptekarRGLawlessOJDeckerJL. Deforming non-erosive arthritis of the hand in systemic lupus erythematosus. Clin Orthop Relat Res1974; 100: 120–124.
2.
DuboisELTuffanelliDL. Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA1964; 190: 104–111.
3.
MakACheungMWChiewHJLiuYHoRC. Global trend of survival and damage of systemic lupus erythematosus: Meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum2012; 41: 830–839.
4.
BernatskySBoivinJFJosephL. Mortality in systemic lupus erythematosus. Arthritis Rheum2006; 54: 2550–2557.
5.
MoscaMBoumpasDTBruceIN. Treat-to-target in systemic lupus erythematosus: Where are we today?Clin Exp Rheumatol2012; 30: S112–S115.
6.
Richter CohenMSteinerGSmolenJSIsenbergDA. Erosive arthritis in systemic lupus erythematosus: Analysis of a distinct clinical and serological subset. Br J Rheumatol1998; 37: 421–424.
7.
Delle SedieARienteLScirèCA. Ultrasound imaging for the rheumatologist. XXIV. Sonographic evaluation of wrist and hand joint and tendon involvement in systemic lupus erythematosus. Clin Exp Rheumatol2009; 27: 897–901.
8.
WrightSFilippucciEGrassiWGreyABellA. Hand arthritis in systemic lupus erythematosus: An ultrasound pictorial essay. Lupus2006; 15: 501–506.
9.
GabbaAPigaMVaccaA. Joint and tendon involvement in systemic lupus erythematosus: An ultrasound study of hands and wrists in 108 patients. Rheumatology (Oxford)2012; 51: 2278–2285.
10.
FernándezAQuintanaGRondónF. Lupus arthropathy: A case series of patients with rhupus. Clin Rheumatol2006; 25: 164–167.
11.
Amezcua-GuerraLM. Comment on: Lupus arthritis – do we have a clinically useful classification?Rheumatology (Oxford)2012; 51: 1521–1523. author reply 1523.
12.
JacobNStohlW. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther2011; 13: 228–228.
13.
ChunHYChungJWKimHA. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol2007; 27: 461–466.
14.
SinghJAFurstDEBharatA. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken)2012; 64: 625–639.
15.
SmolenJSLandewéRBreedveldFC. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis2010; 69: 964–975.
16.
EilertsenGØNikolaisenCBecker-MerokANossentJC. Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus. Lupus2011; 20: 607–613.
17.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
18.
ArnettFCEdworthySMBlochDA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum1988; 31: 315–324.
19.
van der HeijdeDMvan ‘t HofMvan RielPLvan de PutteLB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol1993; 20: 579–581.
20.
YeeCCresswellLFarewellV. Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford)2010; 49: 1665–1669.
21.
PetriMKimMYKalunianKC. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med2005; 353: 2550–2558.
22.
GladmanDGinzlerEGoldsmithC. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363–369.
23.
BackhausMBurmesterGGerberT. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis2001; 60: 641–649.
24.
WakefieldRJBalintPVSzkudlarekM. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol2005; 32: 2485–2487.
25.
SzkudlarekMCourt-PayenMJacobsenSKlarlundMThomsenHSØstergaardM. Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum2003; 48: 955–962.
26.
Amezcua-GuerraLMSpringallRMarquez-VelascoRGómez-GarcíaLVargasABojalilR. Presence of antibodies against cyclic citrullinated peptides in patients with ‘rhupus’: A cross-sectional study. Arthritis Res Ther2006; 8: R144–R144.
27.
BallEMRooneyMRBellAL. Rhupus – an ultrasonographic perspective?Rheumatology (Oxford)2013; 52(Suppl 1): i95–i95.
28.
KarimZWakefieldRJConaghanPG. The impact of ultrasonography on diagnosis and management of patients with musculoskeletal conditions. Arthritis Rheum2001; 44: 2932–2933.
29.
BrownAKConaghanPGKarimZ. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum2008; 58: 2958–2967.
30.
SakellariouGScirèCAVerstappenSMMontecuccoCCaporaliR. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis2013; 72: 245–249.
31.
Andrade-OrtegaLIrazoque-PalazuelosFMuñoz-LópezSRosales-Don PabloVM. Efficacy and tolerability of rituximab in patients with rhupus [in English and Spanish]. Reumatol Clin2013; 9: 201–205.
32.
PigaMGabbaACauliAGarauPVaccaAMathieuZ. Rituximab treatment for ‘rhupus syndrome’: Clinical and power-Doppler ultrasonographic monitoring of response. A longitudinal pilot study. Lupus2013; 22: 624–628.
33.
PetriMOrbaiAAlarcónGS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
34.
WilliamsRCJrHarmonMEBurlingameRDu ClosTW. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol2005; 32: 454–461.
35.
Amezcua-GuerraLM. High-sensitivity C-reactive protein is not a good indicator of infection in patients with systemic lupus erythematosus. Lupus2011; 20: 1567–1568.
36.
GabayCRoux-LombardPde MoerloosePDayerJMVischerTGuernePA. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol1993; 20: 815–821.
37.
SpronkPEter BorgEJKallenbergCG. Patients with systemic lupus erythematosus and Jaccoud’s arthropathy: A clinical subset with an increased C reactive protein response?Ann Rheum Dis1992; 51: 358–361.
38.
Amezcua-GuerraLMMárquez-VelascoRBojalilR. Erosive arthritis in systemic lupus erythematosus is associated with high serum C-reactive protein and anti-cyclic citrullinated peptide antibodies. Inflamm Res2008; 57: 555–557.
39.
WrightHLBucknallRCMootsRJEdwardsSW. Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. Rheumatology (Oxford)2012; 51: 451–459.
40.
AmitalHBarakVWinklerRERubinowA. Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis. Ann N Y Acad Sci2007; 1110: 649–660.
41.
CharlesPElliottMJDavisD. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol1999; 163: 1521–1528.
42.
FeldmannMCharlesPTaylorP. Biological insights from clinical trials with anti-TNF therapy. Springer Semin Immunopathol1998; 20: 211–228.
43.
ShahinAAShakerOGKamalNHafezHAGaberWShahinHA. Circulating interleukin-6, soluble interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-10 levels in juvenile chronic arthritis: Correlations with soft tissue vascularity assessed by power Doppler sonography. Rheumatol Int2002; 22: 84–88.
44.
Kitchen J, Kane D. Correlation of vascular endothelial growth factor and interleukin-6 levels with power Doppler ultrasound of synovial joints in early inflammatory arthritis. Arthritis Rheum 2011; Supplement 10: 195.
45.
KayakabeKKuroiwaTSakuraiN. Interleukin-6 promotes destabilized angiogenesis by modulating angiopoietin expression in rheumatoid arthritis. Rheumatology (Oxford)2012; 51: 1571–1579.
46.
PortaFRadunovicGVladV. The role of Doppler ultrasound in rheumatic diseases. Rheumatology (Oxford)2012; 51: 976–982.
47.
AringerMGraningerWBSteinerGSmolenJS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum2004; 50: 3161–3169.
48.
AringerMHoussiauFGordonC. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: Long-term follow-up of 13 patients. Rheumatology (Oxford)2009; 48: 1451–1454.
49.
IlleiGGShirotaYYarboroCH. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum2010; 62: 542–552.
50.
KraanMCSmeetsTJvan LoonMJBreedveldFCDijkmansBATakPP. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis2004; 63: 1056–1061.
51.
GottenbergJDayerJLukasC. Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: Results from the ESPOIR cohort. Ann Rheum Dis2012; 71: 1243–1248.
